Search by Drug Name or NDC

    NDC 45963-0455-30 Deferasirox 250 mg/1 Details

    Deferasirox 250 mg/1

    Deferasirox is a ORAL TABLET, FOR SUSPENSION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Actavis Pharma, Inc.. The primary component is DEFERASIROX.

    Product Information

    NDC 45963-0455
    Product ID 45963-455_ff13b6ff-e95c-47ed-b21b-6cac71aff318
    Associated GPIs 93100025007330
    GCN Sequence Number 060047
    GCN Sequence Number Description deferasirox TAB DISPER 250 MG ORAL
    HIC3 C8A
    HIC3 Description METALLIC POISON,AGENTS TO TREAT
    GCN 26043
    HICL Sequence Number 033337
    HICL Sequence Number Description DEFERASIROX
    Brand/Generic Generic
    Proprietary Name Deferasirox
    Proprietary Name Suffix n/a
    Non-Proprietary Name Deferasirox
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form TABLET, FOR SUSPENSION
    Route ORAL
    Active Ingredient Strength 250
    Active Ingredient Units mg/1
    Substance Name DEFERASIROX
    Labeler Name Actavis Pharma, Inc.
    Pharmaceutical Class Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A4 Inducers [MoA], Iron Chelating Activity [MoA], Iron Chelator [EPC]
    DEA Schedule n/a
    Marketing Category ANDA
    Application Number ANDA203560
    Listing Certified Through 2024-12-31

    Package

    NDC 45963-0455-30 (45963045530)

    NDC Package Code 45963-455-30
    Billing NDC 45963045530
    Package 30 TABLET, FOR SUSPENSION in 1 BOTTLE (45963-455-30)
    Marketing Start Date 2019-03-22
    NDC Exclude Flag N
    Pricing Information N/A